# Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

> **NCT07236814** · PHASE3 · RECRUITING · sponsor: **Capital Medical University** · enrollment: 384 (estimated)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Suraxavir marboxil
- **DRUG:** Oseltamivir Placebo
- **DRUG:** Oseltamivir
- **DRUG:** Suraxavir marboxil placebo

## Key facts

- **NCT ID:** NCT07236814
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-06
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07236814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07236814, "Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07236814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*